Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | AGL | P35573 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370619 | 1.00 | CPN1 (0.41) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22066364 | 1.00 | CPN1 (0.41) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20568930 | 0.98 | SLC6A2 (0.41) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20568674 | 0.98 | SLC6A2 (0.41) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5729497 | 0.98 | SLC6A2 (0.41) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6488556 | 0.86 | — | — | |
| SCHEMBL6488553 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL28345867 | 0.84 | SLC6A2 (0.36) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6371560 | 0.81 | CPN1 (0.38) | CPN1CPB2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2246490 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-02-03 | — | — | US | disclosed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | disclosed |
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| CN-102952760-B | Rhodococcus erythropolis capable of converting quininone into (S)-3-quinuclidinol and conversion method | TIANJIN INST IND BIOTECHNOLOGY | 2014-04-02 | — | — | CN | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| CN-102952760-A | Rhodococcus erythropolis capable of converting quininone into (S)-3-quinuclidinol and conversion method | TIANJIN INST IND BIOTECHNOLOGY | 2013-03-06 | — | — | CN | disclosed |
| EP-2203437-B1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011149841-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| EP-2325180-A1 | Chiral CIS-imidazolines | F. Hoffmann-La Roche AG (CH) | 2011-05-25 | — | — | EP | disclosed |
| EP-2203437-A1 | CHIRAL CIS-IMIDAZOLINES | F. Hoffmann-Roche AG (CH) | 2010-07-07 | — | — | EP | disclosed |
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN-LA ROCHE, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009047161-A1 | CHIRAL CIS-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| EP-1264827-A1 | Process for the preparation of Tosylbenzylformamides | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| US-4188485-A | NEUROLEPTIC, CORRESPONDING XANTHENES AND THIOANTHENES | G. D. SEARLE & CO. (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111789-A1 | CHIRAL CIS-IMIDAZOLINES | FOXM1, CCNE1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CPN1 2798/4885CPB2 2841/4885SLC6A2 3564/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | CPN1 3795/4885CPB2 3671/4885SLC6A2 3374/4885 |
| US-20220031704-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE9A, PDE5A, PDE2A | CPN1 1312/4885CPB2 1273/4885SLC6A2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.